Methylthioadenosine Phosphorylase (MTAP) Pathway for Genitourinary Cancers
There are several options currently available for the initial treatment of prostate, bladder, and kidney cancer. However, there’re limited resources that exist beyond those therapies if patients do not respond, said Dr. Philippe Spiess, a urologist in the Genitourinary Oncology Department at Moffitt Cancer Center.
To address these needs, researchers have come to understand some of the genetic and biological pathways in these cancers, including the MTAP pathway, which specifically plays a role in carcinogenesis, Spiess adds.
In this video, Dr. Spiess discusses the background and findings of the study, "Genomic classification of clinically advanced major genito-urinary cancers (GUca) based on methylthioadenosine phosphorylase (MTAP) genomic loss," which was presented at the recent 2022 ASCO Genitourinary Cancers Symposium.